Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Texas Oncology - Central Austin Cancer Center
mi
from
Round Rock, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Texas Oncology - Central Austin Cancer Center
mi
from
Round Rock, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Cancer Centers of South Texas - HOAST
mi
from
San Antonio, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Cancer Centers of South Texas - HOAST
mi
from
San Antonio, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Texas Oncology-Waco
mi
from
Waco, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Texas Oncology-Waco
mi
from
Waco, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care
mi
from
Blacksburg, VA
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care
mi
from
Blacksburg, VA
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Puget Sound Cancer Centers
mi
from
Edmonds, WA
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Puget Sound Cancer Centers
mi
from
Edmonds, WA
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Cancer Care Northwest
mi
from
Spokane Valley, WA
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Cancer Care Northwest
mi
from
Spokane Valley, WA
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
City of Hope
mi
from
Duarte, CA
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
Children's Hospital Oakland
mi
from
Oakland, CA
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
Children's Hospital Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
Stanford University Medical Center
mi
from
Palo Alto, CA
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
Stanford University Medical Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
Connecticut Children's Medical Center
mi
from
Hartford, CT
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
Howard University Hospital
mi
from
Washington,
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
Howard University Hospital
mi
from
Washington,
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
Memorial Health University Medical Center
mi
from
Savannah, GA
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
Memorial Health University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
Boston Children's Hospital
mi
from
Boston, MA
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
Children's Hospital of Michigan
mi
from
Detroit, MI
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
Children's Hospital of Michigan
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
Children's Mercy Hospital
mi
from
Kansas City, MO
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
Albert Einstein College of Medicine
mi
from
Bronx, NY
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
University of NC at Chapel Hill School of Medicine
mi
from
Chapel Hill, NC
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
University of NC at Chapel Hill School of Medicine
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
St. Christopher's Hospital for Children
mi
from
Philadelphia, PA
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
St. Christopher's Hospital for Children
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
Medical University of South Carolina
mi
from
Charleston, SC
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
Mary Bridge Children's Hospital and Health Center
mi
from
Tacoma, WA
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
Mary Bridge Children's Hospital and Health Center
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
Emory University
mi
from
Atlanta, GA
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  2/25/2016
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Brussel,
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 2/25/2016
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Brussel,
Click here to add this to my saved trials
Low-Dose Ketamine Infusion for Children With Sickle Cell Disease-Related Pain
Use of Low-Dose Ketamine Infusion in Acute Painful Episodes of Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  2/29/2016
University of Connecticut Health Center
mi
from
Farmington, CT
Low-Dose Ketamine Infusion for Children With Sickle Cell Disease-Related Pain
Use of Low-Dose Ketamine Infusion in Acute Painful Episodes of Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 2/29/2016
University of Connecticut Health Center
mi
from
Farmington, CT
Click here to add this to my saved trials
Low-Dose Ketamine Infusion for Children With Sickle Cell Disease-Related Pain
Use of Low-Dose Ketamine Infusion in Acute Painful Episodes of Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  2/29/2016
Connecticut Children's Medical Center
mi
from
Hartford, CT
Low-Dose Ketamine Infusion for Children With Sickle Cell Disease-Related Pain
Use of Low-Dose Ketamine Infusion in Acute Painful Episodes of Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 2/29/2016
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
A Phase II Study of Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors for Treatment of Hematologic Malignancies and Hematopoietic Failure States
Status: Enrolling
Updated:  3/1/2016
Arizona Cancer Center/University Medical Center
mi
from
Tucson, AZ
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
A Phase II Study of Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors for Treatment of Hematologic Malignancies and Hematopoietic Failure States
Status: Enrolling
Updated: 3/1/2016
Arizona Cancer Center/University Medical Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate
Status: Enrolling
Updated:  3/1/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate
Status: Enrolling
Updated: 3/1/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated:  3/1/2016
The Robert H. Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated: 3/1/2016
The Robert H. Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated:  3/1/2016
Riley Hospital for Children
mi
from
Indianapolis, IN
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated: 3/1/2016
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated:  3/1/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated: 3/1/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated:  3/1/2016
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated: 3/1/2016
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated:  3/1/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated: 3/1/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
A Dose Escalation Study of Intravenous L-citrulline in Steady-state Sickle Cell Disease
Status: Enrolling
Updated:  3/7/2016
University of Mississippi Medical Center
mi
from
Jackson, MS
A Dose Escalation Study of Intravenous L-citrulline in Steady-state Sickle Cell Disease
Status: Enrolling
Updated: 3/7/2016
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Status: Enrolling
Updated:  3/18/2016
Clinical Research Facility
mi
from
Glendale, AZ
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Status: Enrolling
Updated: 3/18/2016
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Status: Enrolling
Updated:  3/18/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Status: Enrolling
Updated: 3/18/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Status: Enrolling
Updated:  3/18/2016
Clinical Research Facility
mi
from
Tempe, AZ
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Status: Enrolling
Updated: 3/18/2016
Clinical Research Facility
mi
from
Tempe, AZ
Click here to add this to my saved trials
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Status: Enrolling
Updated:  3/18/2016
Clinical Research Facility
mi
from
Azusa, CA
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Status: Enrolling
Updated: 3/18/2016
Clinical Research Facility
mi
from
Azusa, CA
Click here to add this to my saved trials
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Status: Enrolling
Updated:  3/18/2016
Clinical Research Facility
mi
from
Long Beach, CA
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Status: Enrolling
Updated: 3/18/2016
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Status: Enrolling
Updated:  3/18/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Status: Enrolling
Updated: 3/18/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Status: Enrolling
Updated:  3/18/2016
Clinical Research Facility
mi
from
Lynwood, CA
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Status: Enrolling
Updated: 3/18/2016
Clinical Research Facility
mi
from
Lynwood, CA
Click here to add this to my saved trials
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Status: Enrolling
Updated:  3/18/2016
Clinical Research Facility
mi
from
Northridge, CA
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Status: Enrolling
Updated: 3/18/2016
Clinical Research Facility
mi
from
Northridge, CA
Click here to add this to my saved trials